Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FLOVENT HFA · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving HFA | EXPERIMENTAL | Subjects in Session 1 will receive two inhalations of placebo HFA by meter-dose inhaler (MDI) twice daily and in Session 2 subjects will receive two inhalations of fluticasone propionate (FP) HFA MDI 44 mcg twice daily |
| Name | Type | Description |
|---|---|---|
| FLOVENT (fluticasone propionate) HFA | DRUG | FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask. |
| Placebo HFA | DRUG | Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask. |
Inclusion Criteria: * Subjects who have experienced 2 or more wheezing episodes in the previous 6 months. * Subjects may not have taken any corticosteroids in the 4 weeks prior to dosing * Parents/guardians should be able to read and comprehend diary information collected throughout the study * Par...
FLOVENT HFA is used for asthma. It is a small molecule respiratory drug developed by GSK plc (ticker: GSK). It is currently in Phase 1 clinical development for this indication.
FLOVENT HFA is developed by GSK plc, which trades under the ticker GSK. The company is conducting clinical research on this small molecule respiratory drug for the treatment of asthma.
FLOVENT HFA is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed to evaluate its use in young children with asthma.
FLOVENT HFA has one completed clinical trial, NCT00370097, titled "FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects." This Phase 1 study enrolled 16 participants with asthma in the United States and was not randomized or blinded.
FLOVENT HFA is a formulation of FLOVENT that uses a hydrofluoroalkane propellant. The clinical trial NCT00370097 specifically evaluated this HFA version in subjects aged 6 to 12 months with asthma.